ROME Therapeutics

About:

ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome.

Website: https://rometx.com/

Top Investors: Alexandria Venture Investments, Andreessen Horowitz, ARCH Venture Partners, Bristol-Myers Squibb, Google Ventures

Description:

ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome – vast stretches of uncharted genetic material that have long been dismissed as “junk DNA.” With several drug targets identified and multiple discovery programs underway, ROME is moving rapidly to leverage this new frontier in biology. To lead this exploration, ROME has assembled a team of world-class leaders across fields including oncology, immunology, virology and machine learning.

Total Funding Amount:

$199M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Cambridge, Massachusetts, United States

Founded Date:

2020-01-01

Founders:

Rosana Kapeller

Number of Employees:

11-50

Last Funding Date:

2023-09-12

IPO Status:

Private

Industries:

© 2025 bioDAO.ai